EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

[News]

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC).

More... (http://www.news-medical.net/news/20131021/EntreMed-presents-preclinical-data-for-ENMD-2076-in-triple-negative-breast-cancer.aspx)